Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334512 · ClinicalTrials.gov registry record · Phase 2
A Study of Quintuple Therapy to Treat COVID-19 Infection
A Phase 2 study, sponsored by ProgenaBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT04334512 is a Phase 2 study that has completed, run by ProgenaBiome. The registered enrollment target is 118 participants.
The verdict
NCT04334512, a Phase 2 study, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
Interventions
- DRUG Azithromycin
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Hydroxychloroquine
- DIETARY_SUPPLEMENT Vitamin C
- DIETARY_SUPPLEMENT Zinc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04334512
The ClinicalTrials.gov registry entry for NCT04334512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProgenaBiome, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Azithromycin is the first listed.
NCT04334512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04334512 about?
NCT04334512 is a clinical study titled "A Study of Quintuple Therapy to Treat COVID-19 Infection". This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).
What is the current status of trial NCT04334512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2020-06-22. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT04334512?
The interventions under investigation include: Azithromycin (DRUG), Vitamin D (DIETARY_SUPPLEMENT), Hydroxychloroquine (DRUG), Vitamin C (DIETARY_SUPPLEMENT), Zinc (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04334512?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.